drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (gene-modified CAR-NK cells)
drug_description
Gene-modified natural killer cells engineered to express a chimeric antigen receptor targeting CLL-1 (CLEC12A) for treatment of relapsed/refractory AML; upon CAR engagement of CLL-1, NK cytotoxic mechanisms (perforin/granzyme, cytokines) kill AML blasts and leukemia stem/progenitor cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Natural Killer Cells
drug_category
CAR NK
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Gene‑modified natural killer cells expressing a CAR that recognizes CLL‑1 (CLEC12A) on AML blasts and leukemia stem/progenitor cells; CAR engagement activates NK cell signaling leading to degranulation and cytotoxic killing via perforin/granzyme and cytokine secretion, with relative sparing of normal hematopoietic stem cells.
drug_name
Anti-CLL-1 CAR NK cells
nct_id_drug_ref
NCT06307054